Addition of receptor tyrosine kinase inhibitor to radiation increases tumour control in an orthotopic murine model of breast cancer metastasis in bone

European Journal of Cancer

Volumn 44, Issue 16, 2008, Pages 2506-2517

  Zwolak, Pawel ^a   Jasinski, Piotr ^a   Terai, Kaoru ^a   Gallus, Nathan J ^b   Ericson, Marna E ^b   Clohisy, Denis R ^b   Dudek, Arkadiusz Z ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Bone cancer pain; Metastatic bone cancer; Radiation; Ras inhibition; SU11248

Indexed keywords

CASPASE; SUNITINIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PAIN; CANCER RADIOTHERAPY; CELL MATURATION; CONTROLLED STUDY; FEMALE; FEMUR; INNERVATION; MICROVASCULATURE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PAIN ASSESSMENT; PRIORITY JOURNAL; RADIOSENSITIZATION; SENSORY NERVE; SPINAL CORD;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE NEOPLASMS; BREAST NEOPLASMS; CASPASES; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; INDOLES; MICE; MICE, SCID; MICROCIRCULATION; PAIN; PYRROLES; RADIATION-SENSITIZING AGENTS; TUMOR BURDEN;

EID: 54349114241     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.07.011     Document Type: Article

References (50)

1. Coleman R.E., and Rubens R.D. The clinical course of bone metastases from breast cancer. Br J Cancer 55 1 (1987) 61-66
2. Perez E.A. Current management of metastatic breast cancer. Semin Oncol 26 4 Suppl. 12 (1999) 1-10
3. Domchek S.M., Younger J., Finkelstein D.M., and Seiden M.V. Predictors of skeletal complications in patients with metastatic breast carcinoma. Cancer 89 2 (2000) 363-368
4. Ripamonti C., and Dickerson E.D. Strategies for the treatment of cancer pain in the new millennium. Drugs 61 7 (2001) 955-977
5. Narazaki D.K., de Alverga Neto C.C., Baptista A.M., Caiero M.T., and de Camargo O.P. Prognostic factors in pathologic fractures secondary to metastatic tumors. Clinics 61 4 (2006) 313-320
6. Wu J.S., Wong R.K., Lloyd N.S., Johnston M., Bezjak A., and Whelan T. Radiotherapy fractionation for the palliation of uncomplicated painful bone metastases - an evidence-based practice guideline. BMC Cancer 4 (2004) 71
7. Rodriguez M.J., Contreras D., Galvez R., et al. Double-blind evaluation of short-term analgesic efficacy of orally administered dexketoprofen trometamol and ketorolac in bone cancer pain. Pain 104 1-2 (2003) 103-110
8. Mystakidou K., Katsouda E., Kouloulias V., Kouvaris J., Tsiatas M., and Vlahos L. Comparison of transdermal fentanyl with codeine/paracetamol, in combination with radiotherapy, for the management of metastatic bone pain. J Opioid Manag 1 4 (2005) 204-210
9. Blum R.H., Novetsky D., Shasha D., and Fleishman S. The multidisciplinary approach to bone metastases. Oncology (Williston Park) 17 6 (2003) 845-857 (discussion 62-3, 67)
10. King T., Gardell L.R., Wang R., et al. Role of NK-1 neurotransmission in opioid-induced hyperalgesia. Pain 116 3 (2005) 276-288
11. Gupta K., Kshirsagar S., Chang L., et al. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res 62 15 (2002) 4491-4498
12. Qasim M.M. Single dose palliative irradiation for bony metastasis. Strahlentherapie 153 8 (1977) 531-532
13. Tong D., Gillick L., and Hendrickson F.R. The palliation of symptomatic osseous metastases: final results of the study by the Radiation Therapy Oncology Group. Cancer 50 5 (1982) 893-899
14. Blitzer P.H. Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasis. Cancer 55 7 (1985) 1468-1472
15. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 1 (2003) 327-337
16. O'Farrell A.M., Abrams T.J., Yuen H.A., et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101 9 (2003) 3597-3605
17. Ostman A., and Heldin C.H. PDGF receptors as targets in tumor treatment. Adv Cancer Res 97 (2007) 247-274
18. Oh H.K., Ha J.M., O E., Lee B.H., Lee S.K., Shim B.S., et al. Tumor angiogenesis promoted by ex vivo differentiated endothelial progenitor cells is effectively inhibited by an angiogenesis inhibitor, TK1-2. Cancer Res 67 10 (2007) 4851-4859
19. Gorski D.H., Beckett M.A., Jaskowiak N.T., et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59 14 (1999) 3374-3378
20. Kozin S.V., Boucher Y., Hicklin D.J., Bohlen P., Jain R.K., and Suit H.D. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 61 1 (2001) 39-44
21. Schueneman A.J., Himmelfarb E., Geng L., et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 63 14 (2003) 4009-4016
22. Griffin R.J., Williams B.W., Wild R., Cherrington J.M., Park H., and Song C.W. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Res 62 6 (2002) 1702-1706
23. Zwolak P., Dudek A.Z., Bodempudi V.D., et al. Local irradiation in combination with bevacizumab enhances radiation control of bone destruction and cancer-induced pain in a model of bone metastases. Int J Cancer 122 3 (2008) 681-688
24. Dudek A.Z., Zwolak P., Jasinski P., et al. Protein kinase C-beta inhibitor enzastaurin (LY317615. HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis. Invest New Drugs 26 1 (2008) 13-24
25. Goblirsch M., Zwolak P., Ramnaraine M.L., et al. Novel cytosine deaminase fusion gene enhances the effect of radiation on breast cancer in bone by reducing tumor burden, osteolysis, and skeletal fracture. Clin Cancer Res 12 10 (2006) 3168-3176
26. Goblirsch M.J., Zwolak P., and Clohisy D.R. Advances in understanding bone cancer pain. J Cell Biochem 96 4 (2005) 682-688
27. Goblirsch M., Mathews W., Lynch C., et al. Radiation treatment decreases bone cancer pain, osteolysis and tumor size. Radiat Res 161 2 (2004) 228-234
28. Murray L.J., Abrams T.J., Long K.R., et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20 8 (2003) 757-766
29. Weber K.L., Doucet M., Price J.E., Baker C., Kim S.J., and Fidler I.J. Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice. Cancer Res 63 11 (2003) 2940-2947
30. Honore P., Luger N.M., Sabino M.A., et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 6 5 (2000) 521-528
31. Lees R.L., and Heersche J.N. Macrophage colony stimulating factor increases bone resorption in dispersed osteoclast cultures by increasing osteoclast size. J Bone Miner Res 14 6 (1999) 937-945
32. Yoneda J., Kuniyasu H., Crispens M.A., Price J.E., Bucana C.D., and Fidler I.J. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 90 6 (1998) 447-454
33. Wacnik P.W., Baker C.M., Herron M.J., et al. Tumor-induced mechanical hyperalgesia involves CGRP receptors and altered innervation and vascularization of DsRed2 fluorescent hindpaw tumors. Pain 115 1-2 (2005) 95-106
34. Pan J., Yeger H., and Cutz E. Innervation of pulmonary neuroendocrine cells and neuroepithelial bodies in developing rabbit lung. J Histochem Cytochem 52 3 (2004) 379-389
35. Lynch J.L., Gallus N.J., Ericson M.E., and Beitz A.J. Analysis of nociception, sex and peripheral nerve innervation in the TMEV animal model of multiple sclerosis. Pain 136 3 (2008) 293-304
36. Mihm M.J., Schanbacher B.L., Wallace B.L., Wallace L.J., Uretsky N.J., and Bauer J.A. Free 3-nitrotyrosine causes striatal neurodegeneration in vivo. J Neurosci 21 11 (2001) RC149
37. Kim I.A., Bae S.S., Fernandes A., et al. Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Res 65 17 (2005) 7902-7910
38. Kim I.A., Fernandes A.T., Gupta A.K., McKenna W.G., and Bernhard E.J. The influence of Ras pathway signaling on tumor radiosensitivity. Cancer Metastasis Rev 23 3-4 (2004) 227-236
39. Dainiak N. Practical and theoretical issues in 1993 concerning radiation effects on the growth of normal and neoplastic hematopoietic cells. Stem Cells 15 Suppl. 2 (1997) 75-85
40. Held K.D. Radiation-induced apoptosis and its relationship to loss of clonogenic survival. Apoptosis 2 3 (1997) 265-282
41. Gillies R.J., Liu Z., and Bhujwalla Z. 31P-MRS measurements of extracellular pH of tumors using 3-aminopropylphosphonate. Am J Physiol 267 1 Pt 1 (1994) C195-203
42. Griffiths J.R. Are cancer cells acidic?. Br J Cancer 64 3 (1991) 425-427
43. Woolf C.J., Allchorne A., Safieh-Garabedian B., and Poole S. Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor alpha. Br J Pharmacol 121 3 (1997) 417-424
44. Suzuki K., and Yamada S. Ascites sarcoma 180, a tumor associated with hypercalcemia, secretes potent bone-resorbing factors including transforming growth factor alpha, interleukin-1 alpha and interleukin-6. Bone Miner 27 3 (1994) 219-233
45. Schwei M.J., Honore P., Rogers S.D., et al. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci 19 24 (1999) 10886-10897
46. Honore P., Rogers S.D., Schwei M.J., et al. Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience 98 3 (2000) 585-598
47. Bruno V., Battaglia G., Casabona G., Copani A., Caciagli F., and Nicoletti F. Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-beta. J Neurosci 18 23 (1998) 9594-9600
48. Hori O., Matsumoto M., Kuwabara K., et al. Exposure of astrocytes to hypoxia/reoxygenation enhances expression of glucose-regulated protein 78 facilitating astrocyte release of the neuroprotective cytokine interleukin 6. J Neurochem 66 3 (1996) 973-979
49. Duda D.G., Jain R.K., and Willett C.G. Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 25 26 (2007) 4033-4042
50. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 5706 (2005) 58-62